Pharchem
Home › Educational Guides › Excipients & Intermediates
Excipients & Intermediates

Pharmaceutical Excipient Qualification and IPEC-GMP Standards

Managing excipient supplier risk, Excipient Information Packages, functionality-related characteristics, and GMP alignment under USP <1078> and EU guidelines.

Why Excipients Require Formal Risk-Based GMP Qualification

Excipients often make up 70% to 90% of a finished tablet, capsule, or liquid formulation by weight. Because many excipients—such as lactose, microcrystalline cellulose, magnesium stearate, and polyethylene glycols—are produced initially for food or industrial markets, verifying pharmaceutical-grade control is essential to prevent diethylene glycol contamination, nitrosamine formation, or batch-to-batch dissolution drift.

In Europe, the Falsified Medicines Directive and EU Guidelines on Formalised Risk Assessment for Excipients (2015/C 95/02) legally require Marketing Authorization Holders to determine appropriate GMP standards for each excipient based on route of administration, source origin, and supply chain complexity.

  • Assess origin risks: mineral, synthetic, plant-derived, or animal-derived (TSE/BSE).
  • Identify distributor repacking or relabeling steps that compromise tamper-evidence.
  • Verify alignment with USP <1078> and the Joint IPEC-PQG GMP Guide.
  • Evaluate nitrosating nitrite trace levels in fillers and disintegrants.

Using IPEC Excipient Information Packages (EIP) to Accelerate Screening

To standardize technical due diligence without forcing every pharmaceutical buyer to send bespoke questionnaires, the International Pharmaceutical Excipients Council (IPEC) developed the standardized Excipient Information Package (EIP). A complete EIP compiles product regulatory status, site GMP details, allergen/TSE/BSE declarations, residual solvents, and supply chain security data.

Reviewing an updated EIP alongside the supplier's third-party EXCiPACT or NSF/IPEC/ANSI 363 certification allows quality teams to triage low-risk oral excipients rapidly while concentrating on-site audits on sterile, injectable, or high-risk functional excipients.

Functionality-Related Characteristics (FRCs) Beyond Basic Monographs

Two excipient lots from different manufacturers can both pass USP-NF or Ph. Eur. chemical monograph tests yet behave differently on a high-speed tablet press. Compendial tests verify chemical purity, whereas Functionality-Related Characteristics (FRCs)—covered in USP <1059> and Ph. Eur. non-mandatory sections—govern physical performance.

Critical FRCs include bulk and tapped density, particle size distribution, specific surface area, moisture sorption, viscosity grade, and degree of substitution. Locking functional ranges into Quality Agreements protects tablet hardness, content uniformity, and dissolution profiles during scale-up.

  • Binders & Fillers: Particle morphology, compressibility, and moisture content.
  • Lubricants (e.g., magnesium stearate): Specific surface area and fatty acid composition.
  • Polymers & Coatings: Molecular weight distribution and solution viscosity.
  • Disintegrants: Swelling index and trace nitrite/peroxide reactivity with APIs.

Control of Elemental Impurities and Reactive Trace Contaminants

Under ICH Q3D, elemental impurities in finished drug products are assessed holistically across APIs, excipients, water, and container-closure systems. Mined mineral excipients such as talc, calcium phosphate, and titanium dioxide can contribute disproportionately to arsenic, lead, or cadmium burdens.

Similarly, trace nitrites in common excipients like crospovidone or pregelatinized starch can react with secondary-amine APIs during shelf life to generate nitrosamines. Requesting quantified trace impurity disclosures from excipient vendors is now central to Quality by Design (QbD) formulation security.

Excipient Risk Assessment & Qualification Matrix

Risk TierTypical Excipient ExamplePrimary Hazard FocusExpected Verification Depth
High (Parenteral / Ophthalmic)Polysorbate 80, Mannitol (IV)Endotoxins, sterility, bioburdenOn-site GMP audit + USP <1078> + full FRC specs
High (Liquid / Glycol)Glycerin, Propylene GlycolDEG / EG adulteration screeningEvery container ID test + audited distributor chain
Moderate (Mined Mineral)Talc, Dibasic Calcium PhosphateICH Q3D heavy metals, asbestos-freeEXCiPACT/NSF audit + batch elemental data
Moderate (Reactive Functional)Crospovidone, Povidone, HPMCPeroxides, trace nitrites, viscosityIPEC EIP + FRC control + trace nitrite disclosure
Lower (Standard Oral Solid)Lactose Monohydrate, MCCTSE/BSE, particle size, moistureIPEC EIP + third-party GMP cert + CoA match

Risk tiers align with EU Guidelines 2015/C 95/02, USP <1078>, USP <1059>, and IPEC-PQG GMP principles.

Worked Illustration: Assessing an Alternative Excipient Vendor

In this worked illustration, assume a solid-oral generics plant wants to qualify a second-source supplier for microcrystalline cellulose (MCC) used in an immediate-release tablet.

  1. Step 1 (Documentation Review): Obtain the vendor's IPEC Excipient Information Package (EIP), EXCiPACT GMP certificate, and ICH Q3D elemental impurity summary.
  2. Step 2 (Distributor Traceability): Confirm the MCC ships in manufacturer-sealed drums with tamper-evident seals and is not open-repacked by an un-audited regional broker.
  3. Step 3 (FRC Benchmarking): Test three supplier lots for USP <1059> bulk density and laser-diffraction particle size; Vendor B shows D50 of 95 microns matching the incumbent 90–105 micron range.
  4. Step 4 (Trace Nitrite & Dissolution Check): Measure trace nitrite levels (<0.5 ppm) and run comparative dissolution on pilot tablets before filing the post-approval change.

Worked Illustration Summary: Validating both compendial purity and Functionality-Related Characteristics ensures seamless tablet press performance with zero dissolution drift.

Excipient Supplier Qualification Checklist

  • Perform a documented risk assessment under EU 2015/C 95/02 or USP <1078>.
  • Collect a current IPEC Excipient Information Package (EIP) and GMP certificate.
  • Verify full supply chain custody from original manufacturer to formulation site.
  • Define Functionality-Related Characteristics (FRCs) alongside monograph limits.
  • Evaluate ICH Q3D elemental impurities and trace reactive species (nitrites/peroxides).
  • Perform mandatory container-by-container identity testing for high-risk glycols.

Frequently Asked Questions

Is full ICH Q7 API GMP required for all pharmaceutical excipients?

No. Excipients follow risk-appropriate GMP standards such as USP <1078>, the Joint IPEC-PQG GMP Guide, or NSF/IPEC/ANSI 363, though high-risk parenteral excipients require stricter controls.

What is EXCiPACT certification?

EXCiPACT is an independent third-party certification scheme verifying that excipient manufacturers and distributors adhere to recognized pharmaceutical excipient GMP and GDP standards.

Why can two USP-compliant excipients behave differently in tableting?

USP chemical monographs test identity and purity, whereas physical Functionality-Related Characteristics—such as particle size, surface area, and bulk density—drive flow and compressibility.

Why must glycerin and propylene glycol undergo heightened testing?

Regulatory agencies mandate strict identity testing for diethylene glycol (DEG) and ethylene glycol (EG) contamination on every container due to historical poisoning incidents.

Primary Standards & Regulatory References

  • USP-NF General Chapter <1078>: Good Manufacturing Practices for Bulk Pharmaceutical Excipients
  • Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients
  • European Commission Guidelines (2015/C 95/02) on Formalised Risk Assessment for Excipients

Related Pharma & Chemical Guides